Telehealth patient acquisition cost by treatment type, and the payback math

Telehealth patient acquisition cost is quoted as if it were a property of the channel. It is closer to a property of the treatment type, because the ad platforms treat a weight-loss ad, a testosterone ad and a hair-loss ad as three different compliance problems, and the friction they impose sets the floor on what a paying patient costs. A founder comparing acquisition figures across categories is comparing three different regulatory environments, and the number alone says little.

What the number does not say is whether the brand can afford it. That is a payback question, and payback is decided by how much of each month's revenue the brand keeps after the medication and the platform are paid. This post covers the definition, the ranges by treatment type, what moves them, and the payback arithmetic that turns an ad rate into a decision.

Cost per consult is not cost per paying patient

Agencies report cost per lead, cost per booked consult and cost per completed consult, and each of those is upstream of the number a brand actually needs, which is cost per patient who pays the first month. Between a completed consult and a paying patient sit three filters. The clinician may decline to prescribe. The patient may be prescribed and not check out. The card may fail on the first charge. Each filter discards some of the acquisition spend that went into the consult.

Take a hypothetical program where a completed consult costs $150 in ad spend and six of every ten completed consults become paying patients. Cost per paying patient is $150 divided by 0.6, or $250. The same brand with a tighter intake questionnaire that screens out ineligible patients before the consult might complete fewer consults at a higher cost each, and convert eight of ten, for a lower cost per paying patient. The consult figure went up and the number that matters went down.

There is a second reason to count at the paying-patient level. On infrastructure that charges a flat fee per completed consult, the consults that do not convert still happened and still carry the fee. At Tessic Health's published $25 per completed consult, a brand converting six of ten pays about $42 in consult fees per paying patient at acquisition, not $25. It is a small line next to a $250 ad cost, and it argues for screening eligibility in the questionnaire rather than the consult.

What the ranges look like by treatment type

There is no audited industry benchmark for telehealth acquisition cost, and any figure quoted without a named source should be read as an estimate. One paid-media agency that runs telehealth accounts has published ranges from its own client data, and they are useful for the ordering rather than the specific dollars. That agency reports roughly $180 to $320 per patient for compounded GLP-1 weight loss, $180 to $300 for testosterone replacement, $70 to $140 for erectile dysfunction, $90 to $170 for hair loss, and $200 to $400 for mental health. Another agency's book would produce different numbers.

The ordering is what is informative. The categories at the low end are the ones where the ad platforms impose the least friction and the purchase decision is fastest: a man searching for a hair-loss treatment or an erectile dysfunction prescription knows what he wants, the ad can say what the product is, and the checkout is short. The categories at the high end are the ones where the platforms restrict targeting, where the claims a brand can make are limited, where the patient has to be screened for eligibility and, in mental health, where the intake itself is longer and the clinician's time per patient is higher.

Within any single category the range is wide, often close to a factor of two, and the spread reflects three levers the brand controls: certification, landing path and eligibility screening.

What moves the number: certification, landing path, eligibility

Certification status is the largest single lever in the regulated categories. Google's advertising policy requires online pharmacies and telemedicine providers to be certified before they can run ads that promote prescription drugs, and it names LegitScript and NABP as recognized certifiers. LegitScript's published healthcare certification pricing is a $975 application fee per website and $2,150 a year, with a $2,500 expedited option, and the certification is recognized by Google, Meta, Microsoft and TikTok. A brand without it is limited to ads that cannot name the medication, which means paying for traffic that has to be educated on the landing page before it can be converted. That is the difference between the low and high end of the agency's ranges in weight loss more than any bidding strategy. The getting approved on Meta and Google Ads guide walks through the application and what the platforms check.

Landing path is the second lever. Every screen between the ad and the questionnaire loses some share of the traffic that paid to arrive. A path that goes ad, product page, eligibility questionnaire, account creation, consult booking, checkout is six steps; a path that goes ad, questionnaire, checkout with the consult scheduled after payment is three. Both are compliant if the clinical review happens before any prescription is written. The shorter path converts more of the same spend, and the cost per paying patient falls without the ad rate changing.

Eligibility friction is the third lever. Meta's health and wellness policy requires weight-loss ads to be targeted to adults 18 and over, and its prescription-drug rules sit under a separate drugs and pharmaceuticals policy, so targeting in the weight-loss category is constrained before the campaign begins. Inside those constraints, a brand that screens hard in the questionnaire spends more per consult and converts more of them; a brand that screens lightly books cheaper consults that the clinician then declines. The paying-patient cost is what reconciles the two approaches, and it usually favors screening early.

Payback math: a flat $25 consult versus a revenue share

Payback is acquisition cost divided by monthly contribution per patient, and it is the number that decides whether an acquisition cost is affordable. Take a hypothetical GLP-1 membership at $229 a month with medication landing at $140 at wholesale and 0 percent markup, consults averaging four per ten patients per month at $25, and card processing at 3 percent. Those inputs are illustrations. Contribution per patient per month before acquisition is $229 minus $140 minus $10 minus $7, about $72. At a $250 acquisition cost, payback is about three and a half months.

Now hold the ad rate and the patient constant and change only the infrastructure agreement to a 30 percent markup on medication and a 10 percent revenue share, with no consult fee, both within the range that appears in white-label agreements. Medication is now $182, the revenue share is about $23, processing is still $7, and contribution falls to about $17 a month. The same $250 acquisition cost now pays back in about fifteen months.

Fifteen months is longer than most GLP-1 patients stay. A JAMA Network Open study available through PubMed Central found that 64.8 percent of patients without type 2 diabetes had discontinued treatment within a year, and a Blue Health Intelligence issue brief reported that roughly 30 percent of patients stopped in the first month. Against that pattern, a fifteen-month payback means the brand loses money on most of the patients it acquires, and a three-and-a-half-month payback means it earns on most of them. The ad cost was identical in both cases. The flat fee versus revenue share guide sets out the contract terms that produce the two outcomes.

A fifteen-month payback means the brand loses money on most of the patients it acquires, and a three-and-a-half-month payback means it earns on most of them. The ad cost was identical in both cases.

This is why the payback question matters more than the acquisition benchmark. A brand at the top of the agency's weight-loss range, paying $320 per patient, has a payback of about four and a half months on the flat-fee structure. A brand at the bottom of the range, paying $180, has a payback of about ten and a half months on the revenue-share structure. The brand with the worse ad rate is in the better position, and the difference is decided by the fee agreement rather than by the media buyer. The unit economics calculator runs this arithmetic for a brand's own inputs.

Channel mix by treatment type

Search works best in the categories where the patient already knows the treatment. Hair loss, erectile dysfunction and testosterone are searched by name, and a certified brand can bid on those terms with ads that say what the product is. Clicks are expensive and patients are cheap, because intent is high.

Paid social carries most weight-loss acquisition, because the audience is broad and the treatment is discovered rather than searched. It also carries the most policy friction: age targeting, claim restrictions and the certification gate. Creative testing matters more here than in search, since the ad has to create the intent that a search ad merely captures. Brands that do well here run many small creative variants against a short landing path.

Owned channels, meaning email and text to a list the brand already holds, are the cheapest per patient and the most regulated per message. Text marketing requires prior express written consent as defined in the FCC's rule at 47 CFR 64.1200(f)(9), and the Telephone Consumer Protection Act sets statutory damages of $500 to $1,500 per message for violations. A brand with a consented list has an acquisition channel that costs almost nothing per send; a brand that texts a list it acquired without that consent has a liability that scales with the size of the list.

Mental health sits apart. The acquisition cost is at the high end of the agency's ranges, the consult is longer, and the patient is often comparing on clinician fit rather than on price, so the channels that work are the ones that let the brand show who the clinicians are: search on condition terms, content that answers pre-booking questions, and referral from adjacent brands.

Brands that already own an audience

Everything above assumes the brand is buying attention from a platform. A brand that already has an audience, whether a creator with a subscriber base, a supplement company with a customer file, a gym with a member roster or a med spa with a patient list, starts with the most expensive part of the funnel already paid for. The acquisition cost for these brands is the cost of the message and the cost of the consult that follows, and it can sit well below any of the ranges an agency would quote for cold traffic.

The constraint for an owned audience is consent and fit rather than cost. A creator's audience gave consent to hear from the creator, not to be marketed a prescription program, and the clinical categories a creator can credibly enter are the ones the audience already trusts the creator on. A fitness brand's members are a natural fit for hormone therapy and weight loss; the same members are not obviously a fit for mental health. The creators page covers how an audience-first brand structures the clinical side so that the audience is offered a program rather than a pitch.

The payback math is the same for these brands, with a smaller numerator. A creator acquiring paying patients at $60 through an owned channel on the flat-fee structure above pays back in under a month; the same creator on the revenue-share structure pays back in three and a half. The gap in months is narrower because the acquisition cost is small; the gap in dollars over the patient's life is just as wide, because the markup and the share are taken every month the patient stays.

Questions operators ask

"What telehealth marketing budget does a new brand need?" Work backward from the target number of paying patients and the payback months. On the hypothetical flat-fee program, a brand that wants to add 50 paying patients a month at $250 each needs $12,500 a month of acquisition spend, and it recovers that spend from those patients about three and a half months later. The brand needs to carry roughly four months of acquisition spend as working capital before the book funds itself; under the revenue-share structure it carries fifteen.

"Is a GLP-1 customer acquisition cost of $300 too high?" Only relative to contribution. At $72 a month of contribution, $300 pays back in just over four months, which is inside the tenure of most patients who stay past the first month. At $17 a month it pays back in a year and a half, which is outside the tenure of most patients in the discontinuation studies. The acquisition figure is not the problem in the second case.

"Does certification pay for itself?" On LegitScript's published pricing, the first year costs $3,125 at the standard pace. If certification moves a brand's weight-loss acquisition cost from the top of the agency's reported range toward the bottom, the difference across a few dozen patients covers the fee. The larger effect is that certification opens the ad inventory that names the medication, which changes which channels are available at all.

"How should a brand set acquisition targets by treatment type?" Set them on payback months rather than on cost. A hair-loss program at $90 per patient and a weight-loss program at $280 per patient can both target a four-month payback and both be right, provided their contribution per month differs in the same proportion. The single figure that should be the same across every category a brand runs is the number of months it is willing to wait to get its money back.